An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Table 3 Solicited and unsolicited potential adverse events associated with levetiracetam

Adverse event	Solicited	Unsolicited
Asthenia		x
Change in weight		x
Cough		x
Effect on mood/behaviour	x
Effect on sleep		x
Gastrointestinal disturbance		x
Nasopharyngitis		x
Rash	x

ISSN: 1745-6215